Human pharmacokinetics of intravenous recombinant human Cu/Zn superoxide dismutase

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 6, 2012, Pages 413-417

  Schaller, Georg ^a   Dittrich, Peter ^b   Felizeter, Manuela ^a   Gouya, Ghazaleh ^a   Leuchten, Nicolai ^a   Kapiotis, Stylianos ^a   Vcelar, Brigitta ^c   Vorauer Uhl, Karola ^d   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

^d UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

Author keywords

Antioxidative defense; Oxidative stress; Recombinant human superoxide dismutase pharmacokinetics

Indexed keywords

RECOMBINANT COPPER ZINC SUPEROXIDE DISMUTASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; STEADY STATE; URINARY EXCRETION;

ADULT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RECOMBINANT PROTEINS; SUPEROXIDE DISMUTASE;

EID: 84861826522     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201651     Document Type: Article

References (21)

1. Sugamura K, Keaney JF Jr. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011; 51: 978-992. doi:10.1016/j.freeradbiomed. 2011.05.004 PubMed
2. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058-1070. doi:10.1161/CIRCRESAHA.110.223545 PubMed
3. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem. 2011; 44: 1189-1198. doi:10.1016/j.clinbiochem.2011.06.988 PubMed
4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-867. doi:10.1038/nature01322 PubMed (Pubitemid 36019639)
5. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001; 53: 135-159. PubMed (Pubitemid 32173112)
6. Droy-Lefaix MT, Drouet Y, Geraud G, Hosford D, Braquet P. Superoxide dismutase (SOD) and the PAF-antagonist (BN 52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic Res Commun. 1991; 12-13: 725-735. doi:10.3109/10715769109145852 PubMed
7. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990; 87: 1620-1624. doi:10.1073/pnas.87.4.1620 PubMed
8. Salvemini D, Wang ZQ, Stern MK, Currie MG, Misko TP. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Natl Acad Sci USA. 1998; 95: 2659-2663. doi:10.1073/pnas.95.5.2659 PubMed
9. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004; 24: 1367-1373. doi:10.1161/01.ATV.0000133604.20182.cf PubMed (Pubitemid 39050427)
10. Vorauer-Uhl K, Wagner A, Katinger H. Long term stability of rh-Cu/Zn-superoxide dismutase (SOD)-liposomes prepared by the cross-flow injection technique following International Conference on Harmonisation (ICH)-guidelines. Eur J Pharm Biopharm. 2002; 54: 83-87. doi:10.1016/S0939- 6411(02)00045-0 PubMed (Pubitemid 34663859)
11. Mikawa K, Nishina K, Maekawa N, Obara H. Attenuation of hyperoxic lung injury in rabbits with superoxide dismutase: effects on inflammatory mediators. Acta Anaesthesiol Scand. 1995; 39: 317-322. doi:10.1111/j.1399-6576.1995.tb040 69.x PubMed
12. Tsao C, Greene P, Odlind B, Brater DC. Pharmacokinetics of recombinant human superoxide dismutase in healthy volunteers. Clin Pharmacol Ther. 1991; 50: 713-720. doi:10.1038/clpt.1991.211 PubMed
13. Uematsu T, Nagashima S, Umemura K, Kanamaru M, Nakashima M. Pharmacokinetics and safety of intravenous recombinant human superoxide dismutase (NK341) in healthy subjects. Int J Clin Pharmacol Ther. 1994; 32: 638-641. PubMed (Pubitemid 24365682)
14. Bayer K, Jungbauer A, Kramer W, Lettner H, Schönhofer W, Skias M, Steindl F, Taferner N, Uhl K. Humane rekombinante Superoxiddismutase. BioEngineering. 1990; 6: 24-30.
15. Vorauer K, Skias M, Trkola A, Schulz P, Jungbauer A. Scale-up of recombinant protein purification by hydrophobic interaction chromatography. J Chromatogr A. 1992; 625: 33-39. doi:10.1016/0021-9673(92)87218-W PubMed
16. Braun E, Wagner A, Fürnschlief E, Katinger H, Vorauer-Uhl K. Experimental design for in vitro skin penetration study of liposomal superoxide dismutase. J Pharm Biomed Anal. 2006; 40: 1187-1197. doi:10.1016/j.jpba.2005.09. 011 PubMed (Pubitemid 43247457)
17. Jaki T, Wolfsegger MJ. Estimation of pharmacokinetic parameters with the R package PK. Pharm Stat. 2010; 10: 284-288. doi:10.1002/pst.449
18. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource 2009.
19. Marzi I, Knee J, Bühren V, Menger M, Trentz O. Reduction by superoxide dismutase of leukocyte-endothelial adherence after liver transplantation. Surgery. 1992; 111: 90-97. PubMed
20. Kaipel M, Wagner A, Wassermann E, Vorauer- Uhl K, Kellner R, Redl H, Katinger H, Ullrich R. Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J Aerosol Med Pulm Drug Deliv. 2008; 21: 281-290. doi:10.1089/jamp.2007.0667 PubMed
21. Vorauer-Uhl K, Fürnschlief E, Wagner A, Ferko B, Katinger H. Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur J Pharm Sci. 2001; 14: 63-67. doi:10.1016/S0928-0987(01)00149-X PubMeddd (Pubitemid 32655416)